Antenatal thiopurine exposure in women with IBD is associated with intrahepatic cholestasis of pregnancy

References

• Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Sep 27;68(Suppl 3):s1–s106. doi: 10.1136/gutjnl-2019-318484
   PubMedGoogle Scholar
• Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17. doi: 10.1093/ecco-jcc/jjab178
   PubMed Web of Science ®Google Scholar
• Torres J, Chaparro M, Julsgaard M, et al. European Crohn’s and colitis guidelines on sexuality, fertility, pregnancy, and lactation. J Crohns Colitis. 2023;17(1):1–27. doi: 10.1093/ecco-jcc/jjac115
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020 Jan 1;14(1):4–22. doi: 10.1093/ecco-jcc/jjz180
   PubMed Web of Science ®Google Scholar
• Hutson JR, Matlow JN, Moretti ME, et al. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol. 2013 Jan;33(1):1–8.
   PubMedGoogle Scholar
• Alami Z, Agier MS, Ahid S, et al. Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study. Therapie. 2018 May;73(3):199–207.
   PubMed Web of Science ®Google Scholar
• Belizna C, Meroni PL, Shoenfeld Y, et al. In utero exposure to azathioprine in autoimmune disease. Where do we stand? Autoimmun Rev. 2020 Sep;19(9):102525.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Long MD, Kane SV, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 2021 Mar;160(4):1131–1139.
   PubMed Web of Science ®Google Scholar
• Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007 Oct;79(10):696–701.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li D, Guo H, et al. Association between thiopurines use and pregnancy outcomes in female patients with inflammatory bowel disease: a meta-analysis. Curr Pharm Des. 2021;27(19):2317–2324. doi: 10.2174/1381612826666200916144249
   PubMed Web of Science ®Google Scholar
• Mozaffari S, Abdolghaffari AH, Nikfar S, et al. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Hum Exp Toxicol. 2015 May;34(5):445–459.
   PubMed Web of Science ®Google Scholar
• Smith DD, Rood KM. Intrahepatic cholestasis of pregnancy. Clin Obstet Gynecol. 2020 Mar;63(1):134–151. doi: 10.1097/GRF.0000000000000495
   PubMed Web of Science ®Google Scholar
• Morton A, Laurie J. The biochemical diagnosis of intrahepatic cholestasis of pregnancy. Obstet Med. 2019 Jun;12(2):76–78. doi: 10.1177/1753495X18795979
   PubMed Web of Science ®Google Scholar
• Lee NM, Brady CW. Liver disease in pregnancy. World J Gastroenterol. 2009 Feb 28;15(8):897–906. doi: 10.3748/wjg.15.897
   PubMed Web of Science ®Google Scholar
• Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol. 2014 Jul;124(1):120–133. doi: 10.1097/AOG.0000000000000346
   PubMed Web of Science ®Google Scholar
• Schneider G, Paus TC, Kullak-Ublick GA, et al. Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic cholestasis of pregnancy. Hepatology. 2007 Jan;45(1):150–158.
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus C, Meier PJ. Pharmacogenetics of hepatocellular transporters. Pharmacogenetics. 2003 Apr;13(4):189–198. doi: 10.1097/00008571-200304000-00003
   PubMedGoogle Scholar
• Pauli-Magnus C, Lang T, Meier Y, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance P-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics. 2004 Feb;14(2):91–102.
   PubMedGoogle Scholar
• Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology. 2004 Aug;40(2):467–474. doi: 10.1002/hep.20336
   PubMed Web of Science ®Google Scholar
• Ovadia C, Seed PT, Sklavounos A, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019 Mar 2;393(10174):899–909. doi: 10.1016/S0140-6736(18)31877-4
   PubMed Web of Science ®Google Scholar
• Lauterbach R, Linder R, Vitner D, et al. Azathioprine-induced cholestasis of pregnancy-A new insight on azathioprine safety in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2020 Jul;250:271–272.
   PubMed Web of Science ®Google Scholar
• Ceruti H, Kayem G, Guilbaud L, et al. Intrahepatic cholestasis of pregnancy associated with azathioprine: a case series. J Gynecol Obstet Hum Reprod. 2021 Apr;50(4):102083.
   PubMed Web of Science ®Google Scholar
• Kanis SL, Modderman S, Escher JC, et al. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. Gut. 2021 Jul;70(7):1266–1274.
   PubMed Web of Science ®Google Scholar
• Lever G, Chipeta H, Glanville T, et al. Perineal outcomes after delivery in 179 mothers with IBD compared to 31,258 controls - a single centre cohort study. J Crohn’s Colitis. 2021 Aug 31;16(3):511–514. doi: 10.1093/ecco-jcc/jjab151
   Google Scholar
• Lever G, Chipeta H, Glanville T, et al. Risk of adverse pregnancy outcomes for women with IBD in an expert IBD antenatal clinic. J Clin Med. 2022 May 22;11(10):2919. doi: 10.3390/jcm11102919
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD parenthood project working group. Gastroenterology. 2019 Apr;156(5):1508–1524.
   PubMed Web of Science ®Google Scholar
• Jharap B, de Boer NK, Stokkers P, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014 Mar;63(3):451–457.
   PubMed Web of Science ®Google Scholar
• Flanagan E, Wright EK, Hardikar W, et al. Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates. Aliment Pharmacol Ther. 2021 Apr;53(7):810–820.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000 Apr;118(4):705–713.
   PubMed Web of Science ®Google Scholar
• Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther. 2004 Apr;75(4):274–281. doi: 10.1016/j.clpt.2003.12.001
   PubMed Web of Science ®Google Scholar
• Saleh MM, Abdo KR. Short communication: consensus on the management of obstetric cholestasis: National UK survey. BJOG. 2006 Jan;114(1):99–103. doi: 10.1111/j.1471-0528.2006.01102.x
   PubMed Web of Science ®Google Scholar
• Chappell LC, Bell JL, Smith A, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet. 2019 Sep 7;394(10201):849–860. doi: 10.1016/S0140-6736(19)31270-X
   PubMed Web of Science ®Google Scholar